Jefferies Maintains a 'Buy' on Myriad Genetics (MYGN); Pricing Mechanism Decided

Jefferies maintains a 'Buy' on Myriad Genetics (NASDAQ: MYGN) price target of $31.00.

Analyst, Jon Wood, said, "Last week, CMS released the much anticipated decision on the appropriate pricing mechanism (gapfill vs. crosswalk) for the new molecular pathology codes. While CMS did not disclose the list of the codes (of the 101 new codes) that it intends to include in the CLFS, it did announce its plan to price the codes (that are eventually included under the CLFS) through the gapfill mechanism."

For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.

Shares of Myriad Genetics closed at $24.99 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• McGraw Hill (MH) PT Raised to $15 at UBS